Share：
Share this content in WeChat
X
[Chinese] [PDF] 24 1
• Review •
CMR radiomics research progress in non-ischemic cardiomyopathy
NIU Meng  WANG Jiajia  WAN Bing  ZHAO Xintian  DONG Yu  LIANG Dongmin  YANG Heng  WANG Gang 

Cite this article as NIU M, WANG J J, WAN B, et al. CMR radiomics research progress in non-ischemic cardiomyopathy[J]. Chin J Magn Reson Imaging, 2026, 17(6): 215-221. DOI:10.12015/issn.1674-8034.2026.06.027.


[Abstract] Cardiovascular diseases remain the leading cause of death and disability worldwide. Non-ischemic cardiomyopathy (NICM), a highly heterogeneous group of disorders, encompasses various subtypes such as dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease, and cardiac amyloidosis. Characterized by complex etiologies and significant variations in clinical manifestations and prognosis, NICM poses substantial challenges for clinical diagnosis and risk stratification. Traditional assessment metrics, such as left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) functional classification, exhibit limited sensitivity and specificity, highlighting the urgent need for more precise risk biomarkers. Cardiac magnetic resonance (CMR), with its superior soft-tissue resolution and multi-parametric imaging capabilities, has emerged as a pivotal tool for evaluating NICM. Radiomics, an emerging high-dimensional feature extraction and analysis technology, enables the mining of deep texture and spatial heterogeneity features from CMR images, offering new perspectives for the precise subtyping and prognosis prediction of NICM. This article reviews the advancements of CMR radiomics in etiological differentiation, risk stratification, and prognosis prediction of NICM, discusses future directions, and provides novel insights for optimizing NICM diagnosis and treatment strategies.
[Keywords] non-ischemic cardiomyopathy；dilated cardiomyopathy；hypertrophic cardiomyopathy；radiomics；cardiac magnetic resonance；risk stratification；myocardial fibrosis

NIU Meng1, 2, 3, 4   WANG Jiajia5   WAN Bing3   ZHAO Xintian3   DONG Yu3   LIANG Dongmin3   YANG Heng3   WANG Gang1, 3, 4*  

1 Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

2 Department of Nuclear Medicine, the Second Hospital of Lanzhou University, Lanzhou 730000, China

3 The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

4 Gansu Provincial Engineering Research Center for Intelligent Medical Imaging, Lanzhou 730000, China

5 General Practice Department, Ruian Municipal People's Hospital, Ruian 325200, China

Corresponding author: WANG G, E-mail: 13893220296@163.com

Conflicts of interest   None.

Received  2026-02-03
Accepted  2026-05-26
DOI: 10.12015/issn.1674-8034.2026.06.027
Cite this article as NIU M, WANG J J, WAN B, et al. CMR radiomics research progress in non-ischemic cardiomyopathy[J]. Chin J Magn Reson Imaging, 2026, 17(6): 215-221. DOI:10.12015/issn.1674-8034.2026.06.027.

[1]
STARK B A, DECLEENE N K, DESAI E C, et al. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023[J]. JACC, 2025, 86(22): 2167-2243. DOI: 10.1016/j.jacc.2025.08.015.
[2]
ARBELO E, PROTONOTARIOS A, GIMENO J R, et al. 2023 ESC guidelines for the management of cardiomyopathies[J]. Eur Heart J, 2023, 44(37): 3503-3626. DOI: 10.1093/eurheartj/ehad194.
[3]
LI K Y, CAI S L. The predictive value of left ventricular ejection fraction and myocardial scar for sudden cardiac death in patients with nonischemic cardiomyopathy[J]. Chin J Card Arrhythm, 2023, 27(1): 81-84. DOI: 10.3760/cma.j.cn113859-20230109-00009.
[4]
MESSROGHLI D R, MOON J C, FERREIRA V M, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J/OL]. J Cardiovasc Magn Reson, 2017, 19(1): 75 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/28992817/. DOI: 10.1186/s12968-017-0389-8.
[5]
LI X, XU Y W, CHEN X Y, et al. Prognostic value of enhanced cine cardiac MRI-based radiomics in dilated cardiomyopathy[J/OL]. Int J Cardiol, 2025, 418: 132617 [2026-02-02]. https://www.internationaljournalofcardiology.com/article/S0167-5273(24)01239-7/abstract DOI: 10.1016/j.ijcard.2024.132617.
[6]
AERTS H J, VELAZQUEZ E R, LEIJENAAR R T, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach[J/OL]. Nat Commun, 2014, 5: 4006 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/24892406/. DOI: 10.1038/ncomms5006.
[7]
MA Z P, WANG S W, XUE L Y, et al. A study on the application of radiomics based on cardiac MR non-enhanced cine sequence in the early diagnosis of hypertensive heart disease[J/OL]. BMC Med Imaging, 2024, 24(1): 124 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/38802736/. DOI: 10.1186/s12880-024-01301-9.
[8]
PU C L, HU X, LV S Y, et al. Identification of fibrosis in hypertrophic cardiomyopathy: a radiomic study on cardiac magnetic resonance cine imaging[J]. Eur Radiol, 2023, 33(4): 2301-2311. DOI: 10.1007/s00330-022-09217-0.
[9]
VAN GRIETHUYSEN J J M, FEDOROV A, PARMAR C, et al. Computational radiomics system to decode the radiographic phenotype[J/OL]. Cancer Res, 2017, 77(21): e104-e107 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/29092951/. DOI: 10.1158/0008-5472.CAN-17-0339.
[10]
BAESSLER B, LUECKE C, LURZ J, et al. Cardiac MRI texture analysis of T1 and T2 maps in patients with infarctlike acute myocarditis[J]. Radiology, 2018, 289(2): 357-365. DOI: 10.1148/radiol.2018180411.
[11]
VRETTOS K, TRIANTAFYLLOU M, MARIAS K, et al. Artificial intelligence-driven radiomics: developing valuable radiomics signatures with the use of artificial intelligence[J/OL]. BJR Artif Intell, 2024, 1(1): ubae011 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/42064395/. DOI: 10.1093/bjrai/ubae011.
[12]
WU L X, DING N, JI Y D, et al. Habitat analysis in tumor imaging: advancing precision medicine through radiomic subregion segmentation[J/OL]. Cancer Manag Res, 2025, 17: 731-741 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/40190416/. DOI: 10.2147/CMAR.S511796.
[13]
FAHMY A S, ROWIN E J, ARAFATI A, et al. Radiomics and deep learning for myocardial scar screening in hypertrophic cardiomyopathy[J/OL]. J Cardiovasc Magn Reson, 2022, 24(1): 40 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/35761339/. DOI: 10.1186/s12968-022-00869-x.
[14]
LAMBIN P, LEIJENAAR R T H, DEIST T M, et al. Radiomics: the bridge between medical imaging and personalized medicine[J]. Nat Rev Clin Oncol, 2017, 14(12): 749-762. DOI: 10.1038/nrclinonc.2017.141.
[15]
HAUPT M, MAURER M H, THOMAS R P. Explainable artificial intelligence in radiological cardiovascular imaging-a systematic review[J/OL]. Diagnostics (Basel), 2025, 15(11): 1399 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/40506971/. DOI: 10.3390/diagnostics15111399.
[16]
WU M J, CHEN A X, GUI Y N, et al. Explainable ML for ACS culprit plaques: a multidimensional CCTA model highlighting hemodynamic increment[J/OL]. Int J Cardiovasc Imaging, 2026 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/41686335/. DOI: 10.1007/s10554-026-03650-8.
[17]
VAZ A, SERRA V C, DE SANTANA RAMOS D O. Beyond volumes and ejection fraction: practical insights into cine-CMR interpretation and applications[J]. Int J Cardiovasc Imaging, 2025, 41(12): 2299-2322. DOI: 10.1007/s10554-025-03530-7.
[18]
TANG Y, MA X, DONG Z X, et al. Cardiac magnetic resonance visualization of the myocardial microstructure in non-ischemic cardiomyopathies[J/OL]. Cardiovasc Innov Appl, 2024, 9(1) [2026-02-02]. https://www.scienceopen.com/hosted-documentdoi=10.15212/CVIA.2024.0042. DOI: 10.15212/cvia.2024.0042.
[19]
SCHOFIELD R, GANESHAN B, FONTANA M, et al. Texture analysis of cardiovascular magnetic resonance cine images differentiates aetiologies of left ventricular hypertrophy[J]. Clin Radiol, 2019, 74(2): 140-149. DOI: 10.1016/j.crad.2018.09.016.
[20]
JIANG S, ZHANG L L, WANG J, et al. Differentiating between cardiac amyloidosis and hypertrophic cardiomyopathy on non-contrast cine-magnetic resonance images using machine learning-based radiomics[J/OL]. Front Cardiovasc Med, 2022, 9: 1001269 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/36386316/. DOI: 10.3389/fcvm.2022.1001269.
[21]
LIU Q M, LU Q F, CHAI Y Z, et al. Papillary-muscle-derived radiomic features for hypertrophic cardiomyopathy versus hypertensive heart disease classification[J/OL]. Diagnostics (Basel), 2023, 13(9): 1544 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/37174935/. DOI: 10.3390/diagnostics13091544.
[22]
IZQUIERDO C, CASAS G, MARTIN-ISLA C, et al. Radiomics-based classification of left ventricular non-compaction, hypertrophic cardiomyopathy, and dilated cardiomyopathy in cardiovascular magnetic resonance[J/OL]. Front Cardiovasc Med, 2021, 8: 764312 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/34778415/. DOI: 10.3389/fcvm.2021.764312.
[23]
LIU D, YU H, CAO J P, et al. Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents in patients with nephropathy[J]. Adverse Drug React J, 2025, 27(11): 667-673. DOI: 10.3760/cma.j.cn114015-20250205-00053.
[24]
WEBER J, BASAK H, LI Y, et al. CMR 2-59 fusion of radiomics and deep-learning features for improved myocardial scar identification for hypertrophic cardiomyopathy from CINE images[J/OL]. J Cardiovasc Magn Reson, 2024, 26: 100141 [2026-02-02]. https://linkinghub.elsevier.com/retrieve/pii/S1097664724001327. DOI: 10.1016/j.jocmr.2024.100141.
[25]
HAN P L, JIANG Z K, GU R, et al. Prognostic prediction of left ventricular myocardial noncompaction using machine learning and cardiac magnetic resonance radiomics[J]. Quant Imaging Med Surg, 2023, 13(10): 6468-6481. DOI: 10.21037/qims-23-372.
[26]
LÜ J, ZHU Y Q, ZHU Y F, et al. Value of CMR radiomics combined with clinical factors in predicting hypertrophic cardiomyopathy complicated by ventricular arrhythmias[J]. Chin J Magn Reson Imaging, 2024, 15(4): 63-71, 87. DOI: 10.12015/issn.1674-8034.2024.04.011.
[27]
ZHANG H B, ZHAO L, WANG H R, et al. Radiomics from cardiovascular MR cine images for identifying patients with hypertrophic cardiomyopathy at high risk for heart failure[J/OL]. Radiol Cardiothorac Imaging, 2024, 6(1): e230323 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/38385758/. DOI: 10.1148/ryct.230323.
[28]
ARYA A, DI BIASE L, BAZÁN V, et al. Epicardial ventricular arrhythmia ablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society, the Latin American Heart Rhythm Society, and the Canadian Heart Rhythm Society[J/OL]. Europace, 2025, 27(4): euaf055 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/40163515/. DOI: 10.1093/europace/euaf055.
[29]
The Cardiomyopathy Specialty Alliance of National Center for Cardiovascular Diseases, Cardiovascular Precision Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. 2025 Chinese guideline for the management of cardiomyopathies[J]. Chin Circ J, 2025, 40(5): 420-462. DOI: 10.3969/j.issn.1000-3614.2025.05.002.
[30]
DI NOTO T, VON SPICZAK J, MANNIL M, et al. Radiomics for distinguishing myocardial infarction from myocarditis at late gadolinium enhancement at MRI: comparison with subjective visual analysis[J/OL]. Radiol Cardiothorac Imaging, 2019, 1(5): e180026 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/33778525/. DOI: 10.1148/ryct.2019180026.
[31]
GARCIA-PAVIA P, RAPEZZI C, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2021, 42(16): 1554-1568. DOI: 10.1093/eurheartj/ehab072.
[32]
FONTANA M, PICA S, REANT P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis[J]. Circulation, 2015, 132(16): 1570-1579. DOI: 10.1161/circulationaha.115.016567.
[33]
ZHOU X Y, TANG C X, GUO Y K, et al. Diagnosis of cardiac amyloidosis using a radiomics approach applied to late gadolinium-enhanced cardiac magnetic resonance images: a retrospective, multicohort, diagnostic study[J/OL]. Front Cardiovasc Med, 2022, 9: 818957 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/35433852/. DOI: 10.3389/fcvm.2022.818957.
[34]
AMYAR A, AL-DEIRI D, SROUBEK J, et al. Radiomic cardiac MRI signatures for predicting ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy[J/OL]. JACC Adv, 2025, 4(4): 101684 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/40127609/. DOI: 10.1016/j.jacadv.2025.101684.
[35]
ALIS D, GULER A, YERGIN M, et al. Assessment of ventricular tachyarrhythmia in patients with hypertrophic cardiomyopathy with machine learning-based texture analysis of late gadolinium enhancement cardiac MRI[J]. Diagn Interv Imaging, 2020, 101(3): 137-146. DOI: 10.1016/j.diii.2019.10.005.
[36]
DURMAZ E S, KARABACAK M, OZKARA B B, et al. Machine learning and radiomics for ventricular tachyarrhythmia prediction in hypertrophic cardiomyopathy: insights from an MRI-based analysis[J]. Acta Radiol, 2024, 65(12): 1473-1481. DOI: 10.1177/02841851241283041.
[37]
SHU S L, WANG C, HONG Z M, et al. Prognostic value of late enhanced cardiac magnetic resonance imaging derived texture features in dilated cardiomyopathy patients with severely reduced ejection fractions[J/OL]. Front Cardiovasc Med, 2021, 8: 766423 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/34977183/. DOI: 10.3389/fcvm.2021.766423.
[38]
FAHMY A S, ROWIN E J, JAAFAR N, et al. Radiomics of late gadolinium enhancement reveals prognostic value of myocardial scar heterogeneity in hypertrophic cardiomyopathy[J]. JACC Cardiovasc Imaging, 2024, 17(1): 16-27. DOI: 10.1016/j.jcmg.2023.05.003.
[39]
WANG J, BRAVO L, ZHANG J Q, et al. Radiomics analysis derived from LGE-MRI predict sudden cardiac death in participants with hypertrophic cardiomyopathy[J/OL]. Front Cardiovasc Med, 2021, 8: 766287 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/34957254/. DOI: 10.3389/fcvm.2021.766287.
[40]
WANG S, LIU C C, GUO Y B, et al. Predicting prognosis of light-chain cardiac amyloidosis by magnetic resonance imaging and deep learning[J]. Eur Heart J Cardiovasc Imaging, 2025, 26(11): 1771-1781. DOI: 10.1093/ehjci/jeaf248.
[41]
NEISIUS U, EL-REWAIDY H, NAKAMORI S, et al. Radiomic analysis of myocardial native T1 imaging discriminates between hypertensive heart disease and hypertrophic cardiomyopathy[J]. JACC Cardiovasc Imaging, 2019, 12(10): 1946-1954. DOI: 10.1016/j.jcmg.2018.11.024.
[42]
SHI R Y, WU R, AN D A L, et al. Texture analysis applied in T1 maps and extracellular volume obtained using cardiac MRI in the diagnosis of hypertrophic cardiomyopathy and hypertensive heart disease compared with normal controls[J/OL]. Clin Radiol, 2021, 76(3): 236.e9-236.e19 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/33272531/. DOI: 10.1016/j.crad.2020.11.001.
[43]
GIRI L, SINGH R, MAREY A, et al. Diagnostic performance of cardiovascular magnetic resonance parametric mapping as per modified Lake Louise Criteria in acute myocarditis: an updated systematic review and meta-analysis[J/OL]. J Cardiovasc Imaging, 2025, 33(1): 5 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/40462222/. DOI: 10.1186/s44348-025-00048-3.
[44]
ZHANG J, XU Y W, LI W H, et al. The predictive value of myocardial native T1 mapping radiomics in dilated cardiomyopathy: a study in a Chinese population[J]. J Magn Reson Imaging, 2023, 58(3): 772-779. DOI: 10.1002/jmri.28527.
[45]
BAEßLER B, MANNIL M, MAINTZ D, et al. Texture analysis and machine learning of non-contrast T1-weighted MR images in patients with hypertrophic cardiomyopathy: Preliminary results[J/OL]. Eur J Radiol, 2018, 102: 61-67 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/29685546/. DOI: 10.1016/j.ejrad.2018.03.013.
[46]
HUANG S, SHI K, ZHANG Y, et al. Texture analysis of T2-weighted cardiovascular magnetic resonance imaging to discriminate between cardiac amyloidosis and hypertrophic cardiomyopathy[J/OL]. BMC Cardiovasc Disord, 2022, 22(1): 235 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/35597906/. DOI: 10.1186/s12872-022-02671-0.
[47]
MANNIL M, KATO K, MANKA R, et al. Prognostic value of texture analysis from cardiac magnetic resonance imaging in patients with Takotsubo syndrome: a machine learning based proof-of-principle approach[J/OL]. Sci Rep, 2020, 10(1): 20537 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/33239695/. DOI: 10.1038/s41598-020-76432-4.
[48]
NAKAMORI S, AMYAR A, FAHMY A S, et al. Cardiovascular magnetic resonance radiomics to identify components of the extracellular matrix in dilated cardiomyopathy[J]. Circulation, 2024, 150(1): 7-18. DOI: 10.1161/CIRCULATIONAHA.123.067107.
[49]
AMYAR A, NAKAMORI S, NGO L, et al. Cardiovascular magnetic resonance radiologic-pathologic correlation in radiomic analysis of myocardium in non-ischemic dilated cardiomyopathy[J/OL]. J Cardiovasc Magn Reson, 2025, 27(1): 101881 [2026-02-02]. https://pubmed.ncbi.nlm.nih.gov/40118277/. DOI: 10.1016/j.jocmr.2025.101881.
[50]
ZHANG X X, CUI C X, ZHAO S F, et al. Cardiac magnetic resonance radiomics for disease classification[J]. Eur Radiol, 2023, 33(4): 2312-2323. DOI: 10.1007/s00330-022-09236-x.
[51]
LASODE J, CHANTAKSINOPAS W, KHONGWIROTPHAN S, et al. Radiomics for differential diagnosis of ischemic and dilated cardiomyopathy using non-contrast-enhanced cine cardiac magnetic resonance imaging[J]. La Radiol Med, 2025, 130(5): 650-661. DOI: 10.1007/s11547-025-01979-z.
[52]
DENG J, ZHOU L T, LI Y Y, et al. Integration of cine-cardiac magnetic resonance radiomics and machine learning for differentiating ischemic and dilated cardiomyopathy[J]. Acad Radiol, 2024, 31(7): 2704-2714. DOI: 10.1016/j.acra.2024.03.032.
[53]
COCKRUM J, NAKASHIMA M, AMMOURY C, et al. Leveraging a vision transformer model to improve diagnostic accuracy of cardiac amyloidosis with cardiac magnetic resonance[J]. JACC Cardiovasc Imaging, 2025, 18(3): 278-290. DOI: 10.1016/j.jcmg.2024.09.010.
[54]
CHANG S, HAN K, SUH Y J, et al. Quality of science and reporting for radiomics in cardiac magnetic resonance imaging studies: a systematic review[J]. Eur Radiol, 2022, 32(7): 4361-4373. DOI: 10.1007/s00330-022-08587-9.
[55]
AKINCI D'ANTONOLI T, CAVALLO A U, VERNUCCIO F, et al. Reproducibility of radiomics quality score: an intra- and inter-rater reliability study[J]. Eur Radiol, 2024, 34(4): 2791-2804. DOI: 10.1007/s00330-023-10217-x.
[56]
JANG J, EL-REWAIDY H, NGO L H, et al. Sensitivity of myocardial radiomic features to imaging parameters in cardiac MR imaging[J]. J Magn Reson Imaging, 2021, 54(3): 787-794. DOI: 10.1002/jmri.27581.
[57]
JENSEN L J, KIM D, ELGETI T, et al. Effects of parametric feature maps on the reproducibility of radiomics from different fields of view in cardiac magnetic resonance cine images- a clinical and experimental study setting[J]. Int J Cardiovasc Imaging, 2025, 41(6): 1173-1184. DOI: 10.1007/s10554-025-03404-y.
[58]
VIEZZER D, HADLER T, GRÖSCHEL J, et al. Post-hoc standardisation of parametric T1 maps in cardiovascular magnetic resonance imaging: a proof-of-concept[J/OL]. eBioMedicine, 2024, 102: 1050551 [2026-02-02]. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00090-2/fulltext. DOI: 10.1016/j.ebiom.2024.105055.
[59]
MANZKE M, LAQUA F C, BÖTTCHER B, et al. Repeatability of radiomic features in myocardial T1 and T2 mapping[J]. Eur Radiol, 2025, 35(3): 1570-1582. DOI: 10.1007/s00330-024-11337-8.

PREV Advances in imaging studies of carotid plaque haemorrhage: From pathological mechanisms to clinical applications
NEXT Research status and progress in pre-treatment evaluation for parametrial invasion of cervical cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn